Press Releases May 13, 2026 04:46 PM

Old National Bancorp Announces Quarterly Dividends

Old National Bancorp Declares Quarterly Dividends on Common and Preferred Shares

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
ONB

Old National Bancorp announced a quarterly cash dividend of $0.145 per common share and $17.50 per preferred share on its 7.0% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series A and Series C. The dividends will be payable mid and late 2026 to shareholders of record in early June and August, respectively. The company is a major commercial bank headquartered in the Midwest, serving primarily the Midwest and Southeast regions, with $73 billion in assets.

Old National Bancorp Announces Quarterly Dividends
ONB
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Old National Bancorp declared a quarterly dividend of $0.145 per common share payable June 15, 2026.
  • A quarterly dividend of $17.50 per share on its 7.0% preferred stock Series A and Series C will be paid on August 20, 2026.
  • The bank is one of the top 25 U.S. banking companies, focusing on long-term client partnerships and community involvement.

EVANSVILLE, Ind., May 13, 2026 (GLOBE NEWSWIRE) -- Old National Bancorp (the “Company” or “Old National”) today announced that its Board of Directors declared a quarterly cash dividend of $0.145 per share on the Company’s outstanding shares of common stock. This quarterly cash dividend will be payable on June 15, 2026, to shareholders of record as of the close of business on June 5, 2026.

In addition, the Board of Directors declared a quarterly cash dividend of $17.50 per share (equivalent to $0.4375 per depositary share or 1/40th interest per share) on Old National’s 7.0% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series A (NASDAQ: ONBPP) and Series C (NASDAQ: ONBPO). The dividends are payable on August 20, 2026, to shareholders of record as of the close of business on August 5, 2026.

ABOUT OLD NATIONAL
Old National Bancorp is the holding company of Old National Bank. As the fifth largest commercial bank headquartered in the Midwest, Old National proudly serves clients primarily in the Midwest and Southeast. With approximately $73 billion of assets and $39 billion of assets under management, Old National ranks among the top 25 banking companies headquartered in the United States. Tracing our roots to 1834, Old National focuses on building long-term, highly valued partnerships with clients while also strengthening and supporting the communities we serve. In addition to providing extensive services in consumer and commercial banking, Old National offers comprehensive wealth management and capital markets services. For more information and financial data, please visit Investor Relations at oldnational.com. In 2025, Points of Light named Old National one of "The Civic 50" - an honor reserved for the 50 most community-minded companies in the United States.

Investor Relations:
Lynell Durchholz
(812) 464-1366
lynell.durchholz@oldnational.com

Media Relations:
Rick Jillson
(812) 465-7267
rick.jillson@oldnational.com


Risks

  • Dividend payments depend on company profitability and may be reduced if financial performance declines.
  • Economic downturns or regional market challenges in the Midwest and Southeast could impact the bank's earnings and dividend sustainability.
  • Changes in interest rates and regulatory environment could affect the bank's capital and dividend policies.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026